RAPT Therapeutics, Inc.
investors.rapt.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2025 10-Q, filed Nov 6, 2025. Its latest SEC filing is a SCHEDULE 13G/A from May 15, 2026.
10-Q for Q3 FY2025, filed Nov 6, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Develops antibody and small-molecule drug candidates for patients with allergic, inflammatory and cancer conditions.
10-K for FY2024, filed Mar 6, 2025
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2025, filed Nov 6, 2025
−$17.6MView ↗
- ▼ −5% (Loss)
- vs −$18.4M in Q3 FY2024
-
Mar 3, 2026
Merger completed; RAPT became a wholly owned subsidiary
The company requested that Nasdaq delist its shares.
Sources
8-K, filed Mar 3, 2026
As described in the Introductory Note above, on March 3, 2026, Purchaser irrevocably accepted for payment all Shares validly tendered and…View ↗
-
Jan 20, 2026
GSK agreed to acquire RAPT for $58.00 per share in cash
Sources
8-K, filed Jan 20, 2026
Pursuant to the Merger Agreement, upon the terms and subject to the conditions thereof, Parent will cause Purchaser to commence a cash…View ↗
Who Did They Compete With?
Competes with LongBio Pharma, United Biopharma, Yuhan, Sanofi, Novartis, Otsuka, Celldex, AstraZeneca, Bristol-Myers Squibb, Merck, Pfizer, Roche/Genentech, Kyowa Hakko Kirin, Agenus/Gilead, and Tusk/Roche
10-K for FY2024, filed Mar 6, 2025RPT904 is a novel long-acting anti-IgE monoclonal antibody intended to treat allergic diseases, including food allergy and CSU. If approved…View ↗
Loading...
